Wide Ranks

BCLI

Brainstorm Cell Therapeutics In

1.74

Top Statistics
Market Cap 9 M Forward PE -1.06 Revenue Growth 0.00 %
Current Ratio 0.50 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2450 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 3 M Total Cash Per Share 0.6530 Total Debt 962000
Total Debt To Equity Current Ratio 0.50 Book Value Per Share -1.21
All Measures
Short Ratio 125.00 % Message Board Id finmb_9048922 Shares Short Prior Month 124587
City New York Uuid 1aa9d83e-cc55-3d11-a3cf-6388b125b02e Previous Close 1.62
First Trade Date Epoch Utc 1 B Book Value -1.21 Beta 0.3910
Total Debt 962000 Volume 148605 Last Split Date 1 B
Fifty Two Week Low 1.05 Total Cash Per Share 0.6530 Shares Short Previous Month Date 1 B
Target Median Price 24.35 Audit Risk 9 Max Age 86400
Sand P52 Week Change 0.3133 Target Mean Price 23.45 Net Income To Common -12746000
Short Percent Of Float 0.0219 Implied Shares Outstanding 5 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 109510 Average Volume10days 109510
Total Cash 3 M Next Fiscal Year End 1 B Held Percent Insiders 0.0904
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 2 Regular Market Previous Close 1.62 Target Low Price 10.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.11 Open 1.62
Free Cashflow -8454750 State NY Dividend Yield 0.00 %
Return On Assets -1.78 Time Zone Short Name EST Board Risk 3
Trailing Eps -3.45 Day Low 1.62 Address1 1325 Avenue of Americas
Shares Outstanding 5 M Compensation Risk 8 Price Hint 4
Target High Price 36.00 Website https://www.brainstorm-cell.com 52 Week Change -0.5857
Average Volume 80172 Forward Eps -2.46 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 45.50 % Last Split Factor 1:15
Regular Market Day High 1.82 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 11.85 Day High 1.82 Shares Short 109802
Regular Market Open 1.62 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0207 Operating Cashflow -14440000
Currency USD Time Zone Full Name America/New_York Market Cap 9 M
Is_nasdaq_100 False Zip 10019 Quote Type EQUITY
Industry Biotechnology Long Name Brainstorm Cell Therapeutics Inc. Overall Risk 5
Regular Market Day Low 1.62 Held Percent Institutions 0.1390 Current Price 1.74
Address2 28th Floor Enterprise To Ebitda -0.2450 Financial Currency USD
Current Ratio 0.50 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 4 M Two Hundred Day Average 5.18
Governance Epoch Date 1 B Enterprise Value 3 M Forward PE -1.06
Regular Market Volume 148605 Ebitda -16036000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases.

Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.